Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua

Vaccine

Volumn 33, Issue 1, 2015, Pages 222-227

  Becker Dreps, Sylvia ^a   Amaya, Erick ^b   Liu, Lan ^c   Rocha, Julio ^d   Briceño, Rafaela ^e   Moreno, Gilberto ^e   Alemán, Jorge ^d   Hudgens, Michael G ^c   Woods, Christopher W ^f   Weber, David J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b National Autonomous University of Nicaragua   (Nicaragua)

^c IL   (United States)

^d Hospital Escuela Dr Oscar Danilo Rosales Arguello (HEODRA)   (Nicaragua)

^e Sistemas Locales de Atención Integral a la Salud León SILAIS León   (Nicaragua)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adults; Nicaragua; Pneumococcal vaccine; Pneumonia; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; HEALTH CARE FACILITY; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; IMMUNIZATION; INCIDENCE; INFLUENZA VACCINATION; MORTALITY; NICARAGUA; REMISSION; STREPTOCOCCUS PNEUMONIA; AGED; AMBULATORY CARE; FEMALE; HEALTH SERVICES RESEARCH; INFANT; MALE; MIDDLE AGED; PNEUMONIA; PREVENTIVE HEALTH SERVICE; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; FEMALE; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; MALE; MIDDLE AGED; NICARAGUA; PNEUMOCOCCAL VACCINES; PNEUMONIA; SURVIVAL ANALYSIS;

EID: 84919396504     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.073     Document Type: Article

References (34)

1. de Quadros C.A. From global to regional: the importance of pneumococcal disease in Latin America. Vaccine 2009, 27(Suppl 3):C29-C32.
2. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
3. Weycker D., Strutton D., Edelsberg J., Sato R., Jackson L.A. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010, 28(31):4955-4960.
4. Jackson M.L., Neuzil K.M., Thompson W.W., Shay D.K., Yu O., Hanson C.A., et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004, 39(11):1642-1650.
5. Said M.A., Johnson H.L., Nonyane B.A., Deloria-Knoll M., O'Brien K.L., et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013, 8(4):e60273. AGEDD Adult Pneumococcal Burden Study Team.
6. Isturiz R.E., Luna C.M., Ramirez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis 2010, 14(10):e852-e856.
7. Alanee S.R., McGee L., Jackson D., Chiou C.C., Feldman C., Morris A.J., et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007, 45(1):46-51.
8. Burgos J., Luján M., Larrosa M.N., Fontanals D., Bermudo G.M., Planes A., et al. Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J 2014, 43(2):545-553.
9. Buzzo A.R., Roberts C., Mollinedo L.G., Quevedo J.M., Casas G.L., Soldevilla J.M. Morbidity and mortality of pneumonia in adults in six Latin American countries. Int J Infect Dis 2013, 17(9):e673-e677.
10. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
11. Jardine A., Menzies R.I., McIntyre P.B. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010, 29(7):607-612.
12. Koshy E., Murray J., Bottle A., Sharland M., Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 2010, 65(9):770-774.
13. Pírez M.C., Algorta G., Cedrés A., Sobrero H., Varela A., Giachetto G., et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J 2011, 30(8):669-674.
14. Ho P.L., Chiu S.S., Chow F.K., Mak G.C., Lau Y.L. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong. Vaccine 2007 Sep 28, 25(39-40):6837-6841.
15. Poehling K.A., Szilagyi P.G., Grijalva C.G., Martin S.W., LaFleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007, 119(4):707-715.
16. Griffin M.R., Zhu Y., Moore M.R., Whitney C.G., Grijalva C.G. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013, 369(2):155-163.
17. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(16):2043-2051.
18. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006, 193(11):1487-1494.
19. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1:CD000422. 10.1002/14651858.CD000422.pub3.
20. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180(1):48-58.
21. World Health Organization (WHO) Weekly Epidemiological Record, Pneumococcal vaccines. WHO position paper-2012 6 April 2012, 87th year. No. 14, 2012, 87, 129-44. Accessed on September 18, 2014 at: http://www.who.int/wer/2012/wer8714.pdf?ua=1.
22. World Health Organization (WHO) Weekly Epidemiological Record 23-valent pneumococcal polysaccharide;1; vaccine-2008. 17 OCTOBER 2008. WHO position paper. Accessed on September 18, 2014 at: http://www.who.int/wer/2008/wer8342.pdf.
23. World Health Organization. Vaccine-preventable diseases: monitoring system. 2013 global summary. Accessed on September 18, 2014 at: http://apps.who.int/immunization_monitoring/globalsummary/schedules.
24. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis 2009, 200(Suppl 1):S39-S48.
25. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995;171(5):1097-106.
26. Becker-Dreps S., Amaya E., Liu L., Moreno G., Rocha J., Briceño R., et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J 2014, 33(6):637-642.
27. Halloran M.E., Struchiner C.J., Longini I.M. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997, 146(10):789-803.
28. World Bank GNI per capita rankings. Accessed on September 18, 2014 at: http://data.worldbank.org/data-catalog/GNI-per-capita-Atlas-and-PPP-table.
29. Nicaraguan Ministry of Health. Programa Nacional de Inmunizaciones, Plan Multianual, 2009-2015. Estado de la Cadena de Frio y Péridads de Vacuna, p. 19. Accessed on September 18, 2014 at: http://www.nationalplanningcycles.org/sites/default/files/country_docs/Nicaragua/planmultianualpnial2015_1.pdf.
30. Nicaraguan Ministry of Health. Normativa 051: Protocol de Atención de Problemas Médicos Más Frecuentes en Adultos, September, 2010. Accessed on September 18, 2014 at: http://www.minsa.gob.ni/index.php/repository/Descargas-MINSA/Direcci%C3%B3n-General-de-Regulaci%C3%B3n-Sanitaria/Normas-Protocolos-y-Manuales/Normas-2010/Normativa---051-Protocolo-de-atenci%C3%B3n-de-problemas-m%C3%A9dicos-m%C3%A1s-frecuentes-en-adultos/.
31. Centers for Disease Control and Prevention. Immunization Coverage in the U.S. 2002 Tables. July 15, 2003. Accessed on September 18, 2014 at: http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/index.html.
32. Simonsen L., Taylor R.J., Young-Xu Y., Haber M., May L., Klugman K.P. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBIO 2011, 2(1):e00309-e310.
33. Fine M.J., Smith M.A., Carson C.A., Meffe F., Sankey S.S., Weissfeld L.A., et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994, 154(23):2666-2677.
34. Matute A.J., Brouwer W.P., Hak E., Delgado E., Alonso E., Hoepelman I.M. Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua. Int J Antimicrob Agents 2006, 28(5):423-427.